Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Department of Pathology, Kobe University, Kobe, Japan.
Lancet. 2015 Apr 11;385(9976):1460-71. doi: 10.1016/S0140-6736(14)60720-0. Epub 2014 Dec 4.
IgG4-related disease is a protean condition that mimics many malignant, infectious, and inflammatory disorders. This multi-organ immune-mediated condition links many disorders previously regarded as isolated, single-organ diseases without any known underlying systemic condition. It was recognised as a unified entity only 10 years ago. Histopathology is the key to diagnosis. The three central pathology features of IgG4-related disease are lymphoplasmacytic infiltration, storiform fibrosis, and obliterative phlebitis. The extent of fibrosis is an important determinant of responsiveness to immunosuppressive therapies. IgG4-related disease generally responds to glucocorticoids in its inflammatory stage, but recurrent or refractory cases are common. Important mechanistic insights have been derived from studies of patients treated by B-cell depletion. Greater awareness of this disease is needed to ensure earlier diagnoses, which can prevent severe organ damage, disabling tissue fibrosis, and even death. Identification of specific antigens and T-cell clones that drive the disease will be the first steps to elucidate the pathogenesis of IgG4-related disease.
IgG4 相关疾病是一种多系统疾病,其临床表现多样,类似于多种恶性疾病、感染性疾病和炎症性疾病。这种多器官免疫介导的疾病将许多以前被认为是孤立的、单一器官疾病联系起来,而这些疾病没有任何已知的系统性疾病基础。仅仅 10 年前,这种疾病才被确认为一种统一的疾病实体。组织病理学是诊断的关键。IgG4 相关疾病的三个核心病理学特征是淋巴浆细胞浸润、席纹状纤维化和闭塞性静脉炎。纤维化的程度是决定对免疫抑制治疗反应性的重要因素。IgG4 相关疾病在炎症期一般对糖皮质激素有反应,但复发或难治性病例很常见。对接受 B 细胞耗竭治疗的患者的研究提供了重要的发病机制见解。提高对这种疾病的认识对于确保早期诊断至关重要,早期诊断可以预防严重的器官损伤、致残性组织纤维化,甚至死亡。鉴定驱动疾病的特定抗原和 T 细胞克隆将是阐明 IgG4 相关疾病发病机制的第一步。
Lancet. 2014-12-4
Odontology. 2018-7-17
Annu Rev Pathol. 2013-10-2
Presse Med. 2020-4
Z Rheumatol. 2016-9
Best Pract Res Clin Rheumatol. 2016-9-6
Diagnostics (Basel). 2025-8-8
Cochrane Database Syst Rev. 2025-8-21
Clin Rheumatol. 2025-8-19
Int J Ophthalmol. 2025-6-18
Eur Arch Otorhinolaryngol. 2025-5-30